Microvast is expected to report Q2 2026 revenue of $94.40 million and a consensus EPS loss of $0.01, with shares trading near $0.81 against a bullish $5.61 average analyst price target.
Investors are primarily focused on the company’s revenue recovery after a sharp 48% year-over-year decline in the first quarter that management described as a temporary setback.
Execution at the Huzhou Phase 3.2 capacity expansion and the initiation of localized pack assemblies at the Clarksville facility are the critical operational milestones needed to support the projected revenue ramp. Market sentiment hinges on whether Microvast can meet its internal target of $103.21 million for the quarter to validate its turnaround story.